Scott Struthers

Co-Founder and Chief Executive Officer
Crinetics

R. Scott Struthers, Ph.D., is Co-founder and Chief Executive Officer of Crinetics Pharmaceuticals. He previously held the role of President and has served on the company’s Board of Directors since 2008.

Prior to Crinetics, Scott was Senior Director and Head of Endocrinology and Metabolism at Neurocrine Biosciences, Inc., where he initiated and led efforts to discover and develop orally active, nonpeptide gonadotropin-releasing hormone antagonists, including elagolix. Earlier in his career, he co-founded ScienceMedia Inc. to develop e-learning solutions for the life sciences and higher education markets, and led computational drug discovery research at Biosym Technologies. In 2009, he co-founded the nonprofit San Diego Entrepreneurs Exchange, where he continues to serve on the board of directors.

Since October 2021, Scott has served as chair of the board of directors at Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications, in which Crinetics holds a minority equity stake.

Scott holds a doctorate in physiology and pharmacology from the University of California, San Diego, based on the work he performed at the Salk Institute for Biological Studies.